Contents

Current Alzheimer Research, Volume 3 - Number 3

Partnerships Between Philanthropy, Government and Investors are Needed to Advance Drug Discovery for Neurodegenerative Diseases

, 3(3): 175 - 176

Lorenzo M Refolo and Howard M Fillit


DOI: 10.2174/156720506777632853




Treatment of Alzheimers Disease: The Beginning of a New Era Dale Schenk, ISOA - October 5th-6th, 2005

, 3(3): 177

Dale Schenk


DOI: 10.2174/156720506777632907




Fibrillar β-Amyloid Impairs the Late Phase of Long Term Potentiation

, 3(3): 179 - 183

Daniela Puzzo and Ottavio Arancio


DOI: 10.2174/156720506777632871




Therapeutic Potential of Neurogenesis for Prevention and Recovery from Alzheimers Disease: Allopregnanolone as a Proof of Concept Neurogenic Agent

, 3(3): 185 - 190

Roberta Diaz Brinton and Jun Ming Wang


DOI: 10.2174/156720506777632817




TGF-β Pathway as a Potential Target in Neurodegeneration and Alzheimers

, 3(3): 191 - 195

Tony Wyss-Coray


DOI: 10.2174/156720506777632916




Neurotrophic Effects of the Peptide NAP: A Novel Neuroprotective Drug Candidate

, 3(3): 197 - 199

Illana Gozes and Irit Spivak-Pohis


DOI: 10.2174/156720506777632790




The Pharmacology of Aminoadamantane Nitrates

, 3(3): 201 - 204

Yuqiang Wang, Jerry Eu, Mark Washburn, Tong Gong, H.-S. Vincent Chen, W. Larrick James, Stuart A. Lipton, Jonathan S. Stamler, Gregory T. Went and Seth Porter


DOI: 10.2174/156720506777632808




De Novo and Molecular Target-Independent Discovery of Orally Bioavailable Lead Compounds for Neurological Disorders

, 3(3): 205 - 214

Laura K. Wing, Heather A. Behanna, Linda J. Van Eldik, D. Martin Watterson and Hantamalala Ralay Ranaivo


DOI: 10.2174/156720506777632844




Ongoing In Vivo Studies with Cytoskeletal Drugs in Tau Transgenic Mice

, 3(3): 215 - 219

Mary L. Michaelis


DOI: 10.2174/156720506777632880




RNA Therapeutics Directed to the Non Coding Regions of APP mRNA, In Vivo Anti-Amyloid Efficacy of Paroxetine, Erythromycin, and N-acetyl cysteine

, 3(3): 221 - 227

Stephanie Tucker, Michelle Ahl, Hyun-Hee Cho, Sanghamitra Bandyopadhyay, Gregory D. Cuny, Ashley I. Bush, Lee E. Goldstein, David Westaway, Xudong Huang and Jack T. Rogers


DOI: 10.2174/156720506777632835




Autoimmunity in Alzheimers Disease as Evidenced by Plasma Immunoreactivity Against RAGE and Aβ42: Complication of Diabetes

, 3(3): 229 - 235

Shyamala Mruthinti, Rosann F. Schade, Dean U. Harrell, Nidhi K. Gulati, S. Swamy-Mruthinti, Gregory P. Lee and Jerry J. Buccafusco


DOI: 10.2174/156720506777632899




NO Chimeras as Therapeutic Agents in Alzheimers Disease

, 3(3): 237 - 245

Gregory R.J. Thatcher, Brian M. Bennett and James N. Reynolds


DOI: 10.2174/156720506777632925




Computational Models of the Hippocampal Region: Implications for Prediction of Risk for Alzheimers Disease in Non-demented Elderly

, 3(3): 247 - 257

Mark A. Gluck, Catherine E. Myers, Michelle M. Nicolle and Sterling Johnson


DOI: 10.2174/156720506777632826




Lipophilic Analogs of Thioflavin S as Novel Amyloid-Imaging Agents

, 3(3): 259 - 266

Chunying Wu, Lisheng Cai, Jingjun Wei, Victor W. Pike and Yanming Wang


DOI: 10.2174/156720506777632862




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science